Nevro Corp - NVRO STOCK NEWS

Nevro Corp. (NYSE: NVRO) announced promising results from its HF10 therapy for chronic pain at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting, held January 14-16. The SENZA-PDN trial, with 216 randomized subjects, demonstrated significant pain relief in Diabetic Neuropathy patients over 6 months. The SENZA-NSRBP trial showed superior outcomes in Non-Surgical Refractory Back Pain patients after 3 months. The data supports a PMA supplement submission to the FDA for U.S. launch activities in the second half of 2021, marking a significant advancement in the treatment of chronic pain.

Nevro Corp. (NYSE: NVRO) announced significant data presentations for its HF10® therapy at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting.

The company will present 20 abstracts, including late-breaking results from the SENZA-PDN and SENZA-NSRBP trials. The SENZA-PDN trial is the largest of its kind, featuring 216 subjects. If approved, this could offer innovative treatment options for patients with chronic pain who have not found relief with traditional methods.

Nevro will also host an investor briefing on January 15, 2021, to discuss business updates.

Nevro Corp. (NYSE: NVRO) announced preliminary, unaudited revenue for Q4 and full-year 2020, revealing a decline in revenue amidst pandemic challenges. Q4 2020 revenue is projected at $109.7 million, a decrease from $114.4 million in Q4 2019. Full-year revenue is expected at $362.0 million, down from $390.3 million. U.S. trial procedures fell approximately 8%. Despite these declines, the company aims to capture market share in the chronic pain sector and anticipates growth as COVID impacts lessen.

Nevro Corp. (NYSE: NVRO) submitted a pre-market approval supplement to the FDA for its Senza® System, targeting Painful Diabetic Neuropathy (PDN). CEO D. Keith Grossman highlighted this milestone as critical for patients lacking relief from pharmacologic treatments. If approved, the Senza System could launch in late 2021, potentially addressing the needs of 4 million U.S. diabetic patients suffering from PDN. The SENZA-PDN study, the largest of its kind, aims to provide safety and efficacy data, with results to be presented at the NANS 2021 meeting on January 15, 2021.

Nevro Corp. (NYSE: NVRO) will host a virtual investor briefing on January 15, 2021, at 4:00 PM PST during the 2021 North American Neuromodulation Society (NANS) Virtual Conference. Chairman and CEO D. Keith Grossman will provide updates on the company's developments, alongside CFO Rod MacLeod and CMO Dr. David Caraway. Key presentations include findings from the SENZA-Painful Diabetic Neuropathy (PDN) trial, the largest RCT of spinal cord stimulation completed, and the Non-Surgical Refractory Back Pain (NSRBP) study. Webcast details can be found on Nevro's website.

Nevro Corp. (NYSE: NVRO), a leader in chronic pain solutions, announced that D. Keith Grossman, Chairman and CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 4:30 PM ET. This event can be accessed via a live webcast available in the Investors section of Nevro's website. Nevro specializes in innovative medical devices, including the Senza spinal cord stimulation system, known for its HF10 therapy that significantly reduces opioid dependency in over 65% of patients.

Nevro Corp. (NYSE: NVRO) announced the dismissal of its patent litigation against Boston Scientific regarding high frequency spinal cord stimulation therapy. This agreement follows Boston Scientific's assurances in July 2018 about not planning to launch a competing system. After a favorable ruling from the U.S. Court of Appeals in April 2020, both parties agreed to drop the remaining claims in California. Ongoing patent cases will continue in Delaware and at the Patent Office for different spinal cord stimulation technologies.

Nevro Corp. (NYSE: NVRO) announced the appointment of Susan E. Siegel to its Board of Directors, effective December 2, 2020, succeeding Wilfred Jaeger. Ms. Siegel brings over thirty years of experience in the life sciences and healthcare sectors, including leadership roles in innovative technology at General Electric and Mohr Davidow Ventures. CEO D. Keith Grossman expressed gratitude to Jaeger for his contributions and welcomed Siegel, highlighting her potential impact on Nevro's growth in chronic pain management products, notably the Senza spinal cord stimulation system.

Nevro Corp. (NYSE: NVRO) has appointed Julie Dewey as the new Vice President of Investor Relations and Corporate Communications, effective immediately. With over 25 years of experience in investor relations and corporate communications within the medical technology sector, Dewey will enhance Nevro's communication strategies with investors and analysts. CFO Rod MacLeod highlighted her extensive background as beneficial for sustainable growth and financial performance. Dewey previously held senior roles at Wright Medical Group and other healthcare technology firms.